In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BMS adds to cancer pipeline in $235mm Kosan takeover

Executive Summary

Bristol-Myers Squibb agreed to buy publicly traded Kosan Biosciences for $235mm (or $190mm after deducting Kosan's projected net cash balance on June 30, 2008), paying $5.50 cash (a 227% premium) for each of the oncology biotech's 42.65mm shares outstanding.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register